Arco Y. Jeng
Novartis Institute for Biomedical Research
Novartis Pharmaceuticals Corporation
Building 435
Room 2191
USA
Name/email consistency: high
- Utility of endothelin-converting enzyme inhibitors for the treatment of cardiovascular diseases. Jeng, A.Y. Curr. Opin. Investig. Drugs (2003)
- Nonpeptidic endothelin-converting enzyme inhibitors and their potential therapeutic applications. Jeng, A.Y., Mulder, P., Kwan, A.L., Battistini, B. Can. J. Physiol. Pharmacol. (2002)
- CGS 34226, a thiol-based dual inhibitor of endothelin converting enzyme-1 and neutral endopeptidase 24.11. Jeng, A.Y., Savage, P., Beil, M.E., Bruseo, C.W., Hoyer, D., Fink, C.A., Trapani, A.J. Clin. Sci. (2002)
- Enhanced expression of matrix metalloproteinase-3, -12, and -13 mRNAs in the aortas of apolipoprotein E-deficient mice with advanced atherosclerosis. Jeng, A.Y., Chou, M., Sawyer, W.K., Caplan, S.L., Von Linden-Reed, J., Jeune, M., Prescott, M.F. Ann. N. Y. Acad. Sci. (1999)
- Suppression of substance P biosynthesis in sensory neurons of dorsal root ganglion by prodrug esters of potent peptidylglycine alpha-amidating monooxygenase inhibitors. Jeng, A.Y., Fujimoto, R.A., Chou, M., Tan, J., Erion, M.D. J. Biol. Chem. (1997)